VI
CDMO capacity & the China exodus
WuXi handles a huge share of Western pipelines; every BIOSECURE headline reprices the non-Chinese CDMO bench.
Who owns it. The Western biopharma pipeline runs through Chinese contract manufacturers to a degree most investors underweight. WuXi AppTec booked RMB45.46bn of 2025 revenue (+15.8% YoY), of which the U.S. market alone was RMB31.25bn — about 68.8% of the total, growing 34.3% year over year (WuXi AppTec FY2025). Sister company WuXi Biologics did RMB21.8bn (+16.7%), carries a US$23.7bn backlog, and reported that roughly half of its 209 new integrated projects in 2025 came from U.S. clients (WuXi Biologics FY2025). That dependency is the chokepoint: a large slice of Western drug substance, antibody-drug conjugates and small-molecule API development sits inside two Chinese platforms that the U.S. government has now formally targeted. The non-Chinese merchant bench that would have to absorb a forced migration is short — Lonza, Samsung Biologics, Fujifilm and a handful of Big-Pharma-adjacent players like Thermo Fisher — and qualified, audited, free capacity is the scarce asset, not square footage.
What breaks it — and what is already breaking. The BIOSECURE Act is no longer a hypothetical. It was signed into law on December 18, 2025 as part of the FY2026 NDAA (Ropes & Gray). On June 8, 2026 the Department of Defense added WuXi AppTec to its Section 1260H list of "Chinese military companies," which triggers one of two statutory pathways to "biotechnology company of concern" status; WuXi's Hong Kong shares fell as much as 8.3% on the news (Ropes & Gray, June 2026). The non-Chinese bench has been building physical capacity into exactly this. Lonza closed its US$1.2bn purchase of Roche/Genentech's Vacaville, California site — ~330,000 L, one of the largest biologics plants in the world — in October 2024 and is investing ~CHF500m upgrading it (Lonza). Fujifilm held the grand opening of its Holly Springs, North Carolina site on September 24, 2025, one of the largest commercial-scale cell-culture sites in North America, anchored by Regeneron and J&J with Phase 1 at 8×20,000 L (Fujifilm). Samsung Biologics brought its 180,000 L Plant 5 into full operation in 2025, lifting Songdo to 785,000 L of total capacity (Samsung Biologics). Thermo Fisher closed the Sanofi Ridgefield NJ sterile site in September 2025 and committed an extra US$2bn to U.S. manufacturing (Thermo Fisher).
What forces the reprice. The tape is regulatory, not quarterly. OMB must publish its initial BCOC list by December 18, 2026; only then does a 180-day guidance clock plus a one-year FAR-revision clock start, and prohibitions for 1260H-designated firms do not bite until 60 days after the FAR is amended — so full federal-procurement enforcement could be ~3 years out (thefdalawblog). That gap between headline and enforcement is the whole trade: every 1260H update, OMB list, and customer dual-sourcing disclosure reprices the bench, while the law's actual teeth arrive slowly. Lonza's Integrated Biologics grew 32.2% in 2025 and management guides 11-12% group CER growth for 2026 (Lonza FY2025); Samsung Biologics grew revenue 30.3% to KRW4.56tn (Pharma Manufacturing). The catalyst flow is the OMB deadline, half-year prints from the bench, and any named program migration off WuXi.
Be honest about size and earliness. This is a slow-motion reprice, not a step-change. WuXi's U.S. business was still growing 34% in 2025 — clients have not actually left; they are dual-sourcing while the enforcement clock runs. The non-Chinese capacity additions are largely operational this cycle (Vacaville integrating, Holly Springs Phase 1 just opened, Plant 5 ramping) but not yet running at the utilization that the bull case assumes, and Fujifilm/Samsung exposure for U.S. investors is only available through thin ADRs or as unlisted names. Lonza, Samsung Biologics and Fujifilm derive the majority of revenue from businesses unrelated to the China-exodus narrative, so the chokepoint is a margin-of-incremental-demand story, not the core of any of these income statements. Treat "announced capacity" (Holly Springs Phase 2, future Lonza expansions) as distinct from the qualified, FDA-inspected, customer-loaded lines that actually constrain a pipeline migration today. This is descriptive of structure and catalysts, not investment advice.
Who owns the choke
Charles River Laboratories International, Inc.
Charles River flagged (per Sept 2024 coverage, around the House BIOSECURE vote) that some VCs were steering portfolio companies away from China-based partners; management later saw preclinical demand bottoming. It launched a strategic review in May 2025 alongside activist Elliott (four new directors) and divested its CDMO business to GI Partners (completed May 2025).
- Bull
- Charles River sits at preclinical and QC chokepoints, with management seeing demand bottoming, an Elliott-backed strategic review, and BIOSECURE steering clients away from Chinese partners.
- Bear
- It divested its CDMO business and faces soft preclinical demand, so the activist-driven turnaround and any BIOSECURE benefit remain unproven for this watch-tier name.
FUJIFILM Holdings Corporation (ADR)
Fujifilm held the grand opening of its Holly Springs, NC biologics site on September 24, 2025 — the largest cell-culture manufacturing site in North America, Phase 1 at 8×20,000 L of a planned US$3.2bn buildout — anchored by Regeneron (a 10-year, >US$3bn agreement) and J&J; Bio CDMO revenue rose 18.5% YoY in fiscal Q3 (Dec-2025 quarter).
- Bull
- Fujifilm opened North America's largest cell-culture site at Holly Springs, anchored by >$3B Regeneron and J&J deals, with Bio CDMO revenue up 18.5% as pipelines reshore off China.
- Bear
- The biologics CDMO is a fraction of the diversified Fujifilm parent reachable only via OTC ADR, and the $3.2bn buildout carries multi-year ramp and utilization risk.
Lonza Group AG (unsponsored ADR)
Lonza's Stein, Switzerland complex performs large-scale commercial biologics filling across vials (liquid and lyophilized), prefilled syringes and cartridges, and is adding a contained ADC filling line targeted to open in 2027. Drug Product was a cited 2025 growth driver. LZAGY is an unsponsored ADR representing one-tenth of a Swiss-listed share.
- Bull
- Lonza spans five chokepoints with its Stein commercial filling complex, a 2027 ADC line, Drug Product as a 2025 growth driver, and CHF6.5bn FY2025 sales with a raised 2026 outlook.
- Bear
- US access is only an unsponsored ADR representing one-tenth of a Swiss share, and broad CDMO exposure leaves it dependent on continued capacity demand it is funding ahead.
Samsung Biologics Co., Ltd.
Samsung Biologics grew FY2025 revenue 30.3% to KRW4.56tn; its 180,000 L Plant 5 reached full operation in 2025, lifting total Songdo capacity to 785,000 L — among the largest contract biologics footprints globally and a primary destination for pipelines migrating off Chinese CDMOs.
- Bull
- Samsung Biologics grew FY2025 revenue 30.3% and lifted Songdo capacity to 785,000L as Plant 5 reached full operation, a primary destination for pipelines migrating off Chinese CDMOs.
- Bear
- It is privately held with no listed exposure vehicle, so investors cannot directly access the China-exodus capacity story through a US-tradable line.
Thermo Fisher Scientific Inc.
Thermo Fisher closed the acquisition of Sanofi's Ridgefield, NJ sterile fill-finish site in September 2025 and announced an additional US$2bn US manufacturing/R&D investment in April 2025; management frames CDMO as the first line of customer reshoring demand and calls its combined sterile network the world's largest fill/finish CDMO.
- Bull
- Thermo Fisher spans five chokepoints, closed Sanofi's Ridgefield fill-finish site, added $2bn US investment, and calls its network the world's largest fill/finish CDMO amid reshoring.
- Bear
- Each chokepoint is one slice of a vast diversified company, so even strong CDMO reshoring demand is diluted within the broader Thermo Fisher portfolio.
WuXi AppTec Co., Ltd.
WuXi AppTec posted RMB45.46bn FY2025 revenue (+15.8%), with the US market alone at RMB31.25bn — ~68.8% of total, +34.3% YoY; it was added to the DoD's Section 1260H 'Chinese military companies' list on June 8, 2026, a statutory trigger toward BIOSECURE 'company of concern' status, and its HK shares fell as much as 8.3% on the news.
- Bull
- WuXi AppTec posted RMB45.46bn FY2025 revenue with US sales up 34.3%, quantifying how much Western work runs on its platform if BIOSECURE pressure eases rather than forces an exit.
- Bear
- Its June 2026 addition to the DoD's 1260H list is a statutory trigger toward BIOSECURE 'company of concern' status, with HK shares already falling up to 8.3%.
WuXi Biologics (Cayman) Inc.
WuXi Biologics reported RMB21.8bn FY2025 revenue (+16.7%) and a US$23.7bn total backlog; roughly half of its 209 new integrated projects in 2025 came from US clients, and it operates 945 integrated programs including 25 in commercial manufacturing — quantifying how much Western biologics work sits on a Chinese platform.
- Bull
- WuXi Biologics grew FY2025 revenue 16.7% to RMB21.8bn with a US$23.7bn backlog and 945 programs, quantifying the Western biologics work sitting on its Chinese platform.
- Bear
- BIOSECURE and the related WuXi AppTec 1260H listing threaten the US client base that supplied roughly half of 2025's new integrated projects, a direct demand overhang.
Catalyst calendar
- 2026-12-18OMB deadline to publish initial BIOSECURE 'biotechnology companies of concern' listhighStatutory one-year deadline that converts the WuXi 1260H designation into a formal BCOC pathway and is the next hard regulatory reprice for the entire CDMO bench.
- 2026-07-22Lonza Half-Year 2026 resultsmediumFirst-half CDMO order intake and Vacaville/Integrated Biologics utilization show whether pipeline migration off Chinese platforms is actually filling the non-Chinese bench.
- 2026-07-29Samsung Biologics Q2 2026 financial resultsmediumPlant 5 utilization and new-order disclosures gauge how fast the largest Asian non-Chinese capacity is absorbing demand redirected by BIOSECURE.
- 2026-11-05Charles River Q3 2026 earnings (estimated)mediumPreclinical booking trends and any strategic-review outcome test whether Western biotechs are de-risking away from China-based research partners as the thesis assumes.